Cargando…

Fexinidazole: A Potential New Drug Candidate for Chagas Disease

BACKGROUND: New safe and effective treatments for Chagas disease (CD) are urgently needed. Current chemotherapy options for CD have significant limitations, including failure to uniformly achieve parasitological cure or prevent the chronic phase of CD, and safety and tolerability concerns. Fexinidaz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bahia, Maria Terezinha, de Andrade, Isabel Mayer, Martins, Tassiane Assíria Fontes, do Nascimento, Álvaro Fernando da Silva, Diniz, Lívia de Figueiredo, Caldas, Ivo Santana, Talvani, André, Trunz, Bernadette Bourdin, Torreele, Els, Ribeiro, Isabela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486905/ https://www.ncbi.nlm.nih.gov/pubmed/23133682 http://dx.doi.org/10.1371/journal.pntd.0001870

Ejemplares similares

Benznidazole and Posaconazole in Experimental Chagas Disease: Positive Interaction in Concomitant and Sequential Treatments
por: Diniz, Lívia de Figueiredo, et al.
Publicado: (2013)

Benznidazole/Itraconazole Combination Treatment Enhances Anti-Trypanosoma cruzi Activity in Experimental Chagas Disease
por: Assíria Fontes Martins, Tassiane, et al.
Publicado: (2015)

Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness
por: Torreele, Els, et al.
Publicado: (2010)

Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice
por: Diniz, Lívia de Figueiredo, et al.
Publicado: (2018)

Synergic Effect of Allopurinol in Combination with Nitroheterocyclic Compounds against Trypanosoma cruzi
por: Mazzeti, Ana Lia, et al.
Publicado: (2019)

Determination of an Optimal Dosing Regimen for Fexinidazole, a Novel Oral Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Studies
por: Tarral, Antoine, et al.
Publicado: (2014)

A Phase 2, Randomized, Multicenter, Placebo-Controlled, Proof-of-Concept Trial of Oral Fexinidazole in Adults With Chronic Indeterminate Chagas Disease
por: Torrico, Faustino, et al.
Publicado: (2022)

Fexinidazole interferes with the growth and structural organization of Trypanosoma cruzi
por: Zuma, Aline Araujo, et al.
Publicado: (2022)

Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole
por: Watson, James A., et al.
Publicado: (2019)

Innovative Partnerships for the Elimination of Human African Trypanosomiasis and the Development of Fexinidazole
por: Neau, Philippe, et al.
Publicado: (2020)

Development and Introduction of Fexinidazole into the Global Human African Trypanosomiasis Program
por: Valverde Mordt, Olaf, et al.
Publicado: (2022)

Nutrition, Diabetes and Tuberculosis in the Epidemiological Transition
por: Dye, Christopher, et al.
Publicado: (2011)

The European Medicines Agency’s scientific opinion on oral fexinidazole for human African trypanosomiasis
por: Pelfrene, Eric, et al.
Publicado: (2019)

Fexinidazole for Human African Trypanosomiasis, the Fruit of a Successful Public-Private Partnership
por: Bernhard, Sonja, et al.
Publicado: (2022)

Mir-190b negatively contributes to the Trypanosoma cruzi- infected cell survival by repressing PTEN protein expression
por: Monteiro, Cíntia Júnia, et al.
Publicado: (2015)

Role of cyclooxygenase-2 in Trypanosoma cruzi survival in the early stages of parasite host-cell interaction
por: Moraes, Karen CM, et al.
Publicado: (2015)

Experimental Trypanosoma cruzi Infection and Chagas Disease—A Word of Caution
por: Talvani, André, et al.
Publicado: (2023)

Myenteric plexus is differentially affected by infection with distinct Trypanosoma cruzi strains in Beagle dogs
por: Nogueira-Paiva, Nívia Carolina, et al.
Publicado: (2013)

Efficacy and Toxicity of Fexinidazole and Nifurtimox Plus Eflornithine in the Treatment of African Trypanosomiasis: A Systematic Review
por: Hidalgo, Jessica, et al.
Publicado: (2021)

Modelling the impact of fexinidazole use on human African trypanosomiasis (HAT) transmission in the Democratic Republic of the Congo
por: Das, Aatreyee M., et al.
Publicado: (2021)

Nitroimidazooxazoles(#) Part xxiv, Search for Antileishmanial Agents: 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles as Potential Antileishmanial Agents
por: Shashiprabha,, et al.
Publicado: (2014)

Discovery, Development, Inventions and Patent Review of Fexinidazole: The First All-Oral Therapy for Human African Trypanosomiasis
por: Imran, Mohd, et al.
Publicado: (2022)

A Bioluminescence-Based Drug Screen Identifies Activities of Fexinidazole and Its Metabolites against Helicobacter pylori
por: Mohamed, Abdolhakim, et al.
Publicado: (2022)

Business-as-Usual will not Deliver the COVID-19 Vaccines We Need
por: Torreele, Els
Publicado: (2020)

Poly-ε-Caprolactone Implants for Benznidazole Prolonged Release: An Alternative to Chagas Disease Oral Treatment
por: Mazzeti, Ana Lia, et al.
Publicado: (2023)

The Role of Co-Stimulatory Molecules in Chagas Disease
por: Pinto, Bruna F., et al.
Publicado: (2018)

Ensuring access to life-saving medicines as countries shift from Global Fund support
por: Tatay, Mercedes, et al.
Publicado: (2019)

Managing the risks of making the wrong diagnosis: First, do no harm
por: Olliaro, Piero, et al.
Publicado: (2021)

Global challenges in preparedness and response to epidemic infectious diseases
por: Olliaro, Piero, et al.
Publicado: (2022)

We Cannot Win the Access to Medicines Struggle Using the Same Thinking That Causes the Chronic Access Crisis
por: Krikorian, Gaëlle, et al.
Publicado: (2021)

COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room
por: Olliaro, Piero, et al.
Publicado: (2021)

COVID-19 vaccines: effectiveness and number needed to treat – Authors' reply
por: Olliaro, Piero, et al.
Publicado: (2021)

Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study
por: Kande Betu Ku Mesu, Victor, et al.
Publicado: (2021)

Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2–3 trial
por: Kande Betu Kumesu, Victor, et al.
Publicado: (2022)

Prognosis of chronic Chagas heart disease and other pending clinical challenges
por: Torres, Rosália Morais, et al.
Publicado: (2022)

Neuronal Parasitism, Early Myenteric Neurons Depopulation and Continuous Axonal Networking Damage as Underlying Mechanisms of the Experimental Intestinal Chagas' Disease
por: Ricci, Mayra Fernanda, et al.
Publicado: (2020)

Timing of Pharyngeal Swallow Events in Chagas’ Disease
por: dos Santos, Carla Manfredi, et al.
Publicado: (2014)

Vimentin and Anti Vimentin Antibodies in Chagas' Disease
por: Nascimento, Marilda Savoia, et al.
Publicado: (2018)

Assessing the mitochondrial DNA diversity of the Chagas disease vector Triatoma sordida (Hemiptera: Reduviidae)
por: Pessoa, Grasielle Caldas D‘Ávila, et al.
Publicado: (2016)

How to ensure a needs-driven and community-centred vaccination strategy for COVID-19 in Africa
por: Boum II, Yap, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kfefpce80nci7lffg6lu5rmj58